Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04805983 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT04805983: Completed Phase 1 study, sponsored by Yale University.
NCT04805983 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04805983, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This project seeks to develop a novel disease-modifying compound for Alzheimer's disease (AD).
Primary Outcome
A count of participants that experience any adverse events found to be associated with treatment. All adverse events are summarized in the adverse events section.
Interventions
- DRUG BMS-984923
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-03-25 |
| Est. Completion | 2022-04-24 |
| Phase | Phase 1 |
What the finished NCT04805983 record still lists
NCT04805983 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 1 intervention - of which BMS-984923 is the first listed.
NCT04805983 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04805983 about?
NCT04805983 is a clinical study titled "Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923". This project seeks to develop a novel disease-modifying compound for Alzheimer's disease (AD).
What is the current status of trial NCT04805983?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2021-03-25. Estimated completion is 2022-04-24.
What interventions are being tested in trial NCT04805983?
The interventions under investigation include: BMS-984923 (DRUG).
Who is sponsoring clinical trial NCT04805983?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04805983's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI